Одну секунду
Что-то сучилось. Попробуйте еще раз.
Braf смотреть последние обновления за сегодня на .
BRAF is a gene that makes a protein called B‐Raf. BRAF is involved in sending signals within cells that direct their growth. Identification of the BRAF V600 mutation and development of BRAF targeting drugs have radically changed clinical practice and outcomes of advanced or metastatic melanoma.
Dr. Karen Kelly explains what a BRAF-V600E fusion is in lung cancer. BRAF-V600E is an important biomarker that can impact your treatment options. Talk to your doctor about comprehensive biomarker testing. Visit 🤍lung.org/braf for more information. Support for this educational program provided by Amgen, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech, Lilly Oncology, Merck, Novartis and Pfizer.
Activating mutations in the BRAF oncogene are now well established as critical drivers of melanoma and other malignancies and represent rational targets for the development of novel therapeutics. Jordi Rodon emphasizes that a current picture is much more complex than the model of one biomarker, one drug, in this case BRAF mutation in melanoma and vemurafenib. In this video, he discusses the role of BRAF mutations in non-melanoma tumours and how the use of new models of clinical trials (like Basket trials), new drugs and drug combinations are enabling the study of the relevance of BRAF alterations in oncology. The study of the role of BRAF in other tumours serves as an example to depict some important concepts in precision cancer medicine. Distinction between mutation, copy-number gain and gene rearrangements and how it may impact drug efficacy, the role of lineage and genomic content, and the different agents in the MAPK pathway are profoundly discussed. Produced by the European Society for Medical Oncology 🤍
Wellcome Trust Sanger Institute scientist Ultan McDermott tells the story of BRAF. This gene was discovered to be mutated in 40% of malignant melanoma by researchers who sequenced cancer genomes. As a result drugs have been developed to target a particular mutation in BRAF prolonging the life of people with this form of cancer. This video has been produced to accompany a classroom activity: BRAF: from gene to cancer therapy that has been developed by the Public Engagement team at the Wellcome Trust Sanger Institute. The activity is available at 🤍yourgenome.org
This cancer pathway lecture explains about the braf mutation and braf inhibitors. 🤍 Get Shomu's Biology DVD set here- 🤍 Download the study materials here- 🤍 Remember Shomu’s Biology is created to spread the knowledge of life science and biology by sharing all this free biology lectures video and animation presented by Suman Bhattacharjee in YouTube. All these tutorials are brought to you for free. Please subscribe to our channel so that we can grow together. You can check for any of the following services from Shomu’s Biology- Buy Shomu’s Biology lecture DVD set- 🤍shomusbiology.com/dvd-store Shomu’s Biology assignment services – 🤍shomusbiology.com/assignment -help Join Online coaching for CSIR NET exam – 🤍shomusbiology.com/net-coaching We are social. Find us on different sites here- Our Website – 🤍shomusbiology.com Facebook page- 🤍 Twitter - 🤍 SlideShare- 🤍slideshare.net/shomusbiology Google plus- 🤍 LinkedIn - 🤍 Youtube- 🤍 Thank you for watching
Jeffrey S. Weber, MD, PhD; Hussein Tawbi, MD, PhD; Omid Hamid, MD; and Jason J. Luke, MD, FACP, discuss molecular profiling and considerations for selecting therapy in metastatic melanoma.
This mechanism of action (MOA) animation was a first for our client: an MOA for consumer education on social media. We wrote a concise script using plain language and created an accessible visual identity for the molecules and cells, with a bright and bold color palette. The lively pace and punchy animation, with custom music by Zach Kellum, deliver high science concepts in a format that is easy to understand, within the 60 second time limit of Instagram. This melanoma MOA animation was launched in support of Melanoma Awareness Month, in sync with ASCO 2020. Scientific animations are highly effective at educating professional and patient audiences about complex medical and scientific concepts. Have your own science story to tell? We can help. sales🤍axs3d.com
Halfdan Sorbye, MD, professor, Department of Oncology and Medical Physics, Haukeland University Hospital, University of Bergen, discusses the survival differences in KRAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC).
Lung Cancer Video Library 🤍
Сигнальные каскады в молекулярных структурах, молекулярные нарушения BRAF и особенности исследований BRAF-ингибиторов. Лектор: Федор Владимирович Моисеенко, д.м.н. Заведующий Онкологическим химиотерапевтическим (противоопухолевой лекарственной терапии) биотерапии отделением, ГБУЗ «Санкт-Петербургский Клинический научно-практический центр специализированных видов медицинской помощи (онкологический)» ВКонтакте: 🤍 Сайт: 🤍
In this segment, Bruce E. Johnson, MD, and Mark A. Socinski, MD, discuss V600E, a specific type of BRAF mutation detected in certain patients with non–small cell lung cancer, and highlight the types of therapy used to treat this patient population.
Харкевич Галина Юрьевна (Москва) Научно-практический семинар «Актуальные вопросы иммунотерапии солидных опухолей» Telegram 🤍 YouTube 🤍 Facebook 🤍 VK 🤍 Instagram 🤍 Twitter 🤍
Bruce E. Johnson, MD, and Roy S. Herbst, MD, PhD, describe the potential role for dabrafenib/trametinib in non–small cell lung cancer and the importance of multipanel mutation testing.
Keith T. Flaherty, MD, director of Developmental Therapeutics at the Cancer Center of Massachusetts General Hospital, discusses resistance that develops in patients with BRAF-mutant melanoma.
Treatment options for BRAF V600E–mutated colorectal cancer and other BRAF variants. For more resources and information regarding anticancer targeted therapies: 🤍
Hossein Borghaei, DO, reviews the case of a 69-year-old male with BRAF V600E-mutated metastatic non–small cell lung cancer and highlights the importance of molecular testing in every patient with this diagnosis. For more resources and information regarding anticancer targeted therapies: 🤍
Patient and Caregiver Symposium held in Charlotte, NC at Levine Cancer Institute in which leading melanoma experts, Dr. Richard White, Dr. Asim Amin, Dr. Jeffrey Infante, Dr. Sanjiv Agarwala, and Dr. Omid Hamid discuss melanoma treatments.
Axel Hauschild, MD, PhD of University Hospital Schleswig-Holstein, Kiel, Germany, gives an overview of his talk on dabrafenib and trametinib for melanoma therapy held at the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria. According to Prof. Hauschild, it was great to see that a BRAF and a MEK inhibitor (dabrafenib and trametinib respectively) were better than the BRAF inhibitor (dabrafenib) alone (NCT01584648). This set a new standard of care for BRAF-mutated melanomas according to Prof. Hauschild; the response rate was a high as 70%, which is very significant. Further, the response duration was one year and progression-free surival (PFS) and overall survival (OS) were better for the combination compared to the single agent treatment (OS was 44% after three years).
Имянитов Евгений Наумович Диагностика метастатической меланомы и роль BRAF-тестинга. Молекулярные аспекты развития резистентности и значимость концепции двойного воздействия на MAPK-путь - Современная лекарственная терапия меланомы кожи 2017 - YouTube 🤍 Facebook 🤍 VK 🤍 Instagram 🤍
At the European Cancer Congress (ECC) 2015, Dirk Schadendorf, MD, PhD, of Universitätsklinikum Essen, Essen, Germany, discusses the advances in the understanding of BRAF-mutant melanoma biology, which involves the constitutive activation of the MAPK pathway, that have led to the development of new targeted therapies for patients with metastatic disease.
ΔΕΣ ΟΛΑ ΤΑ ΜΠΡΑΦ ΕΔΩ: 🤍 ΟΧΙ. ΔΕΝ ΘΑ ΚΑΝΩ ΑΛΛΟ ΜΠΡΑΦ. Να το ξεκαθαρισω. Αλλα υπηρχε ενα τελευταιο επεισοδιο που δεν είδε ποτέ το φως της ημέρας. Παρτε το στην ωμη, ακυκλοφορητη μορφη του, οπως ακριβως το βρηκα στον παλιο σκληρο δισκο.
Filip Janku, MD, PhD, assistant professor, Department of Investigational Cancer Therapeutics, University of Texas, MD Anderson Cancer Center, discusses longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers. This study was presented at the 2014 ASCO Annual Meeting. More from this meeting: 🤍
Biologia de la via de señales de BRAF #BRAF #BRAF testing #melanoma #MAPK #BRAF biology
Siekiant didinti informuotumą ir supratimą apie BRAF geno mutaciją, gegužės 26 d. yra paskelbta melanomos su BRAF geno mutacija žinomumo diena. Šią dieną siūloma kalbėtis apie patikrą, ką ši mutacija reiškia paciento diagnozei, užmegzti glaudesnį dialogą tarp gydytojo ir paciento, suteikti žmonėms, kuriems diagnozuota melanoma su BRAF geno mutacija, pasitikėjimo. Socialinėje erdvėje prie šių pokalbių galima prisijungti naudojantis grotažymėmis #MelanomaAwarenessMonth, #Melanoma, #SkinCancer, #MelanomaBRAFAwarenessDay.
Presentation by Luca Gerosa at the single-cell proteomics conference: 🤍 🤍 Playlist of all videos 🤍 See more related videos at 🤍 Cancer cells treated with targeted inhibitors of oncogenic pathways can escape treatment through homeostatic adaptation of their signaling networks, a phenomenon termed ‘adaptive resistance’. Our limited ability to predict the response of signaling pathways to drug perturbations is a key obstacle to design drug strategies that can prevent adaptive resistance. Here, we use experiments and computational modeling to build predictive models of drug adaptation in colorectal, thyroid and skin cancers bearing BRAF V600E, a mutation that is present in up to 50% of these cancers and is responsible for hyper-activation of the pro-growth RAF/MEK/ERK signaling pathway. We hypothesize that adaptive resistance to targeted kinase inhibitors in these cancers is governed by their lineage-specific receptor dynamics and feedback regulation strengths. By incorporating the biochemistry of ERK signaling and the mechanisms of action of targeted drugs into an Ordinary Differential Equation model, we reproduced the adaptive response of these cancers to targeted inhibitors. To validate and extend the model, we generated time-course, single-cell data using multiplexed immunofluorescence and live-cell imaging and discovered that single-cell ERK signaling dynamics determine the adaptive drug resistance of these cancers. For more details see the bioRxiv preprint at: 🤍
Wir hatten dieses Video ob der titelgebenden Vielfalt etwas nach hinten geschoben, zu unterschiedlich verhalten sich die verschiedenen Klassen der #BRAF Mutationen bezüglich der therapeutischen Optionen. Unsere Lösung: Wir behandeln in diesem Video ausschließlich Klasse I #Mutationen und legen dann in einem #DeepDives Video zeitnah nach... Klasse I Mutationen sind die V600X-Mutationen, allen voran BRAF V600E. Sie führen zu einer Aktivierung des eminent wichtigen MAPK-pathways bereits als Monomer - alle anderen BRAF-Mutationen sind dazu nicht in der Lage. Spezifische BRAF-Inhibitoren hemmen das Monomer sehr effizient und sind deshalb fester Bestanteil der Therapie von BRAF V600E - mit drei Schwächen: 1. Wird MEK nicht ausreichend unterdrückt - die Kombination mit einem MEK-Inhibitor ist zwingend erforderlich. 2. Alleinige BRAF-Inhibierung kann zu Paradoxer Aktivierung führen. 3. Erworbene Resistenz erscheint unweigerlich - man weiß nur nicht genau. WIE. Dennoch ist viel in Mache - der Nachweis der Mutationen in so vielen Krebsarten wie #Melanom, #Lungenkrebs, #Darmkrebs und auch #Schilddrüsenkrebs zeigen hier einen klaren Bedarf nach verbesserter Krebstherapie. Nochmal zur Erinnerung: RAF-Inhibitoren tragen das Kürzel im Namen, die MEK-Inhibitor verweisen auf MET. Unser #shorts Video aus dem Adventskalender 2022: 🤍 UNTERTITEL IN KÜRZE! Sollten Sie oder Bekannte betroffen sein, empfehlen Wir die Kontaktaufnahme zu folgendem Verein: 🤍 - Deutscher Verein für Patienten mit Lungenkrebs und zielgerichtet therapierbarer Mutationen. 00:00 Krebsmutationen: BRAF 00:32 Was ist das eigentlich (SKIP INTRO)? 01:48 RAF A B C 02:07 RAF Dimerisierung 04:31 Bei welchen Krebsarten kommt das vor? 05:26 Woher kommt das? 07:26 Wie therapiert man das? 09:55 Paradoxe Aktivierung 11:46 Resistenzen 13:11 Immuntherapie 15:42 Was macht die Forschung? 16:56 TAKE HOME (Outro) Unser Video zu Rezeptor-Tyrosin-Kinasen: 🤍 Unser Video zu ALK-Fusionen: 🤍 Unser Video zu TP53-Mutationen: 🤍 Unser Video zu KRAS-Mutationen: 🤍 _ Musik: "368" von Jobii [Epidemic Sound] Artwork: HealthCareSocialMedia
Blessie Elizabeth Nelson, MBBS, DMRT, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses how BRAF rechallenge and retreatment impact tumor histology beyond melanoma. Patients exposed to RAF inhibitors in the first cohort had complete or partial responses, and when rechallenged with a RAF2 inhibitor, a shorter response duration was reported. Progression-free survival (PFS) and overall survival (OS) in both the RAF1 and RAF2 cohorts were similar, and patients had a higher metastatic burden when exposed to the RAF2 inhibitor. Treatment breaks were found to have no significance on response. Combination therapies with RAF inhibitors and investigational therapies contributed to inferior outcomes. Genomic studies showed that the BRAF V600E aberration continued despite two rechallenges. Further study is required to understand these acquired mechanisms of resistance, especially after rechallenge. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Breve descripcion de las metodologias de testeo de las mutaciones del gen BRAF. #BRAF #braf testing #melanoma #colorectal carcinoma #cancer
СУПЕРКУБОК Бучанського району в сезоні 2022/2023 років
Vemurafenibe está no rol da ANS para o tratamento do câncer metastático com mutação V600 do gene BRAF, primeira linha. A mutação V600 do gene BRAF é uma alteração genética que afeta a proteína BRAF. O gene BRAF é responsável pela produção da proteína BRAF, que desempenha um papel importante na regulação do crescimento e da divisão celular. A mutação V600 é uma das mutações mais comuns no gene BRAF e ocorre quando uma letra do DNA é alterada, resultando em uma mudança de aminoácido na proteína BRAF. Especificamente, a mutação V600 substitui a valina pelo ácido glutâmico na posição 600 da proteína BRAF. Essa mutação ativa o sinal de crescimento celular de forma anormal, levando a uma maior proliferação celular e ao desenvolvimento de tumores. A mutação V600 do gene BRAF está associada a vários tipos de câncer, incluindo melanoma, câncer colorretal, câncer de pulmão, câncer de tireoide e outros. O teste genético é usado para identificar a presença da mutação V600 do gene BRAF em amostras de tecido ou sangue, permitindo que os médicos escolham o tratamento mais adequado para o paciente com base em sua mutação genética específica. Vemurafenibe é um medicamento aprovado pela FDA (agência reguladora de medicamentos dos EUA) e pela Anvisa para o tratamento de melanoma metastático com mutação BRAF V600E ou V600K. É um inibidor de BRAF e MEK, proteínas que regulam o crescimento celular e a divisão celular. Algumas indicações específicas para Vemurafenibe incluem: - Tratamento de melanoma metastático com mutação BRAF V600E ou V600K. - Em combinação com cobimetinibe, outro inibidor de MEK, para o tratamento de melanoma avançado com mutação BRAF V600. - Em combinação com atezolizumabe, um anticorpo monoclonal anti-PD-L1, para o tratamento de melanoma metastático com mutação BRAF V600 e expressão de PD-L1. - Em combinação com cetuximabe, um anticorpo monoclonal anti-EGFR, para o tratamento de carcinoma de células escamosas da cabeça e pescoço com mutação BRAF V600E. Contudo, muitas vezes a recomendação de Vemurafenibe se dá pela alteração genética em si e não propriamente pelo tumor. Mas o que fazer se o plano de saúde recusar? E é sobre isto que o professor de Direito Médico e Hospitalar da USP de Ribeirão Preto, Elton Fernandes, advogado especialista em planos de saúde, fala neste vídeo. Saiba, por exemplo, que a Lei dos Planos de Saúde estabelece que o rol da ANS pode ser superado sempre que a recomendação médica tiver respaldo técnico-científico, sendo possível buscar a cobertura do tratamento. Acompanhe o vídeo e descubra como lutar por seu direito! Não importa o nome do plano de saúde, tampouco se é um plano empresarial, individual, coletivo por adesão - como os planos da Qualicorp -, se é um plano familiar ou autogestão, tampouco se a operadora de saúde é a Bradesco, Sul América, Unimed, Cassi, Cabesp, Notredame, Intermédica, Allianz, Porto Seguro, Amil, Marítima Sompo, São Cristóvão, Prevent Senior, Hap Vida ou qualquer outra. Havendo indicação médica baseada em ciência, será possível lutar pela cobertura do Vemurafenibe mesmo fora das situações elencadas pela ANS. Quer saber mais? Confira também este artigo em nosso blog: 🤍 Siga nossas redes sociais e visite nosso site: ▷ Facebook: 🤍 ▷ Instagram: 🤍 ▷ Site: 🤍 Entre em contato: ▷ E-mail: contato🤍eltonfernandes.com.br ▷ Telefone: (11) 3141-0440 ▷ WhatsApp: (11) 97751-4087 O escritório do advogado Elton Fernandes é inscrito na OAB/SP sob n.º 16.616, é especialista em ações contra planos de saúde, SUS, Direito Médico e Hospitalar, seguros etc.
Отвечаю на вопросы подписчиков ▼▼▼ Честные ответы на ваши вопросы по поводу рака кишечника. Задать свой вопрос можно у меня в Инстаграме, подписывайтесь по ссылке: 🤍 Больше информации здесь 🤍
Join us for "Brif, Braf, Bruf" the fourth episode of Gianni Rodari’s 𝗧𝗲𝗹𝗲𝗽𝗵𝗼𝗻𝗲 𝗧𝗮𝗹𝗲𝘀. Sometimes a made-up language is the most universal language of all. Bruf! "Telephone Tales" is a series of 12 short, sweet stories for kids by beloved Italian children’s author, 𝗚𝗶𝗮𝗻𝗻𝗶 𝗥𝗼𝗱𝗮𝗿𝗶, in a new English translation by Antony Shugaar, with Illustrations by Valerio Vidali. A co-production of the Embassy of Italy, the Italian Cultural Institute in Washington, DC and Enchanted Lion Books.
Credyd Ffilmio, golygu a chyfarwyddo: Elen Mair Williams, Adran Theatr, Ffilm a Theledu, Prifysgol Aberystwyth. Ffilmio Drôn: Scott Waby Am fwy o wybodaeth, ewch i: 🤍 Dilynwch ni ar: Facebook: 🤍 Twitter: 🤍 Gwobr Aur am Fframwaith Rhagoriaeth Addysgu (TEF 2018), a Phrifysgol y Flwyddyn ar gyfer Ansawdd Addysgu (The Good University Guide, the Times and Sunday Times 2018), mae prifysgol Aberystwyth yn un o'r prifysgolion gorau yng Nghymru am fodlonrwydd myfyrwyr (ACF 2017). Am fwy o wybodaeth, ewch i: 🤍 Dilynwch ni ar: Facebook: 🤍 Twitter: 🤍
[Oncoinfo – Istantanee di Oncologia: seguici su 🤍] Il trattamento con BRAF inhibitors è un’arma importante nel melanoma, ma anche nel tumore del polmone e del colon. Paolo Ascierto (SC Oncologia Medica Melanoma Immunoterapia Oncologica e Terapie Innovative, Istituto Nazionale Tumori IRCCS Fondazione Pascale di Napoli) presenta la nuova monografia "Mutazioni del gene BRAF nei tumori solidi" (Il Pensiero Scientifico editore), un volume che si occupa in modo esaustivo delle mutazioni, delle terapie correlate e delle prospettive future.
Απλα... Θ Α Ν Α Τ Ο Ο Ο Σ ! ! !
Para saber mais informações sobre câncer, tratamento, prevenção e bem estar visite 🤍 Visite também nossa página do facebook 🤍
#medicalknowledgeonline , What is BRAF Genetic Test ?, What is it used for?, Why do need this test?, What happens during test?, Is need any preparation for the test?, How long for the test ? Are any risks to this test?, what show Results ?, What know more about the test?, - Medical Lab Tests - What is ? , Uses , Need , Preparation , Results #medicalknowledgeonline * TOPICS 1. ANATOMY – Topics 🤍 2. PHYSIOLOGY – Topics 🤍 3. DISEASES – Topics 🤍 4. PUBLIC HEALTH- Topics 🤍 5. Rx – Topics 🤍 6. LABORATORY TEST – Topics 🤍 7. MEDICAL IMAGING – Topics 🤍 8. SURGICAL AND MEDICAL PROCEDURES – topics 🤍 9. MICROBIOLOGY – Topics 🤍 10. BIOCHEMISTRY – Topics 🤍 11. NUTRITION – Topics 🤍 12. HEALTH TOPICS 🤍 13. MEDICAL & SURGICAL – Topics 🤍 14. PAEDIATRICS / CHILD HEALTH – Topics 🤍 15. MENTAL HEALTH – Topics 🤍 16. MATERNAL HEALTH – Topics 🤍 17. COMMUNITY HEALTH – Topics 🤍 18. NURSING FOUNDATION – Topics 🤍 19. BIOSTATISTICS – Topics 🤍 20. PATHOLOGY – TOPICS 🤍 21. NURSING EDUCATION – Topics 🤍 22. HOSPITAL MANAGEMENT AND HEALTH CARE ADMINISTRATION – Topics 🤍 23. NURSING RESEARCH – TOPICS 🤍 24. NURSING FOUNDATION – Topics 🤍 25. PHARMACOLOGY – TOPICS 🤍 26. PUBLIC HEALTH – Topics 🤍 27. INTERNATIONAL DAYS 🤍 28. NURSING - TOPICS 🤍 #medicalknowledgeonline
Superwichtig und beim Melanom auch relativ häufig sind #BRAF Mutationen. v. A. die stark aktivierenden V600X-Mutationen, wovon wiederum die V600E-Mutation am Häufigsten vorkommt. Neben dem Melanom spielen diese Mutationen eine wichtige Rolle bei Darmkrebs, Lungenkrebs, sog. Haarzell-Leukämien, Glioblastomen und spezielle Schilddrüsenkrebsformen, u. a.. Andere BRAF-Mutationen werden funktionell in andere Klassen eingeteilt - hier dann mehr zu in Unserem längeren BRAF-Video. V600E lässt sich zielgerichtet therapieren: Die spezifischen BRAF-Inhibitoren erkennen Sie an der Endung "-rafenib". ABER: Dadurch wird die Signalübertragung nicht gänzlich herunter gefahren, zusätzlich muss auch MEF (MAP2K1) inhibiert werden (mit den "-metinibs") - mehr dazu in Kürze! Musik: "House Hunt" von Dylan Sitts [Epidemic Sound]
.svg){kind=small}
